|
|
News Breaks | | | | November 12, 2012 | | 07:06 EDT |  | ABT | Abbott announces long-term patient-reported health outcomes data for Humira
Abbott announced the first long-term patient-reported health outcomes data from an open-label analysis of the ongoing, Phase 3 ABILITY-1 trial of Humira, or adalimumab. The study evaluated improvements in physical function and health-related quality of life, or HRQOL, after 52 weeks in patients with active non-radiographic axial spondyloarthritis. The HRQOL was assessed using the Short Form 36 Health Survey score. 77 percent of patients met the MID for SF-36 Physical Component Summary score of 3.0 at week 52. Placebo patients who switched to open-label Humira experienced improvements in HRQOL comparable to patients who received Humira through week 52. By week 52, patients in both groups achieved SF-36 scores, expressed on a scale of 0-100, where higher scores indicate better health and well-being. | |
|
News For ABT From The Last 14 Days Check below for free stories on ABT the last two weeks. |
|
|
| May 22, 2013 | | 07:28 EDT |  | ABT | UBS to host a conference
Global Healthcare Services Conference is being held in New York on May 20-22 with webcasted company presentations to begin on May 22 at 8 am; not all company presentations may be webcasted. Webcast Link | | | May 21, 2013 | | 08:03 EDT | | ABT | Abbott announces CE Mark for coronary drug eluting stent
 Subscribe for More Information | | | May 20, 2013 | | 10:11 EDT |  | ABT | On The Fly: Analyst Upgrade Summary
Subscribe for More Information | | | 06:01 EDT | | ABT | Abbott upgraded to Buy from Neutral at Goldman
Goldman upgraded Abbott to reflect accelerating growth driven by emerging markets, better growth and product mix, new product launches, and market share gains. Price target raised to $44 from $38. | | | May 9, 2013 | | 07:04 EDT | | ABT | Abbott announces CE Mark for A1c test
Subscribe for More Information | |
|
|
|
|
|
|
